Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE in combination with Dexamethasone or VELCADE in combination with Dexamethasone and Cyclophosphamide or VELCADE in combination with Dexamethasone and Lenalidomide in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after Primary Therapy for Multiple Myeloma and have achieved stable disease after 4 cycles of VELCADE/Dexamethasone therapy

Trial Profile

A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE in combination with Dexamethasone or VELCADE in combination with Dexamethasone and Cyclophosphamide or VELCADE in combination with Dexamethasone and Lenalidomide in Subjects with Multiple Myeloma who are Refractory to or Have Relapsed / progressed after Primary Therapy for Multiple Myeloma and have achieved stable disease after 4 cycles of VELCADE/Dexamethasone therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms SEQUENTIAL
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2012 Actual patient number is 163 according to ClinicalTrials.gov.
    • 07 Jun 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top